Baker Bros. Invests $33M in Replimune Offering, Boosting Stake to 11.8%
REPL has more than doubled off its 52-week low of $1.5.
Summary
Baker Bros. Advisors purchased $33 million of pre-funded warrants in Replimune's public offering, raising its stake to 11.8% and reinforcing institutional confidence following the recent FDA approval of TUDRIQEV.
Key Events · Ownership and Investor Activity · REPL
-
Baker Bros. Invests $33M in Offering
Baker Bros. Advisors LP purchased 2,736,340 pre-funded warrants at $12.0599 each, totaling $32,999,986.77, in Replimune's public offering that closed today.
-
Ownership Stake Rises to 11.8%
The purchase increases Baker Bros.' beneficial ownership to 11,075,336 shares (11.8% of outstanding), based on 83,945,161 shares outstanding plus 9,701,490 new shares from the offering.
-
Warrants Subject to Ownership Blockers
The pre-funded warrants cannot be exercised if Baker Bros.' ownership would exceed 4.99% (for $0.0001 warrants) or 9.99% (for $0.001 warrants), preventing immediate conversion to common stock.
-
Director Lock-Up Agreement
Director Michael Goller entered a lock-up agreement restricting sales of his shares until September 24, 2026, aligning his interests with the offering.
Analysis · REPL · Life Sciences
Baker Bros. Advisors, a prominent life sciences investor, purchased $33 million of pre-funded warrants in Replimune's just-closed public offering, increasing its beneficial ownership to 11.8%. The investment comes just days after the company received FDA accelerated approval for its first commercial product, TUDRIQEV, and signals strong institutional conviction in the commercial launch. The warrants are structured with 4.99% and 9.99% beneficial ownership blockers, meaning Baker Bros. cannot immediately exercise them into common stock, but the purchase locks in a significant economic interest at the offering price. This filing also reveals a director lock-up agreement through September 24, 2026, further aligning insider interests with the offering.
At the time of this filing, REPL was trading at $13.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $1.50 to $14.14. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.